Review
Neurosciences
Simon R. W. Stott, Richard K. Wyse, Patrik Brundin
Summary: The international Linked Clinical Trials program is focused on providing disease-modifying drugs for Parkinson's disease, with seven completed and 15 ongoing clinical trials. This program, which has rapidly grown since its initial planning in 2010, aims to deliver disease modification in PD by evaluating 16 agents in clinical trials. The review provides an overview of the history, structure, process, progress, and examples of agents selected and evaluated by the program.
FRONTIERS IN NEUROSCIENCE
(2021)
Article
Pharmacology & Pharmacy
Daphna Laifenfeld, Chen Yanover, Michal Ozery-Flato, Oded Shaham, Michal Rosen-Zvi, Nirit Lev, Yaara Goldschmidt, Iris Grossman
Summary: Research utilizing real-world healthcare data has identified two drugs with significant beneficial effects on Parkinson's disease progression, providing insights into potential disease-modifying therapeutic solutions.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Clinical Neurology
Hao-Yun Chang, Ying-Yu Li, Chien-Tai Hong, Yi-Chun Kuan
Summary: Rasagiline monotherapy at 1 mg per day is recommended for patients with early Parkinson's disease due to its benefits for motor and nonmotor functions and its safety.
JOURNAL OF PSYCHOPHARMACOLOGY
(2022)
Article
Neurosciences
Jose M. M. Bispo, Joao E. C. Melo, Auderlan M. Gois, Katty A. A. L. Medeiros, Rodolfo Santos Silva, Pollyana C. Leal, Heitor S. Franco, Marina F. Souza, Livia C. R. F. Lins, Alessandra M. Ribeiro, Regina H. Silva, Jose R. Santos
Summary: Research suggests that testosterone treatment can reduce damage caused by reserpine in a rat model of Parkinson's disease and improve motor behavior and dopamine depletion.
BRAIN RESEARCH BULLETIN
(2022)
Review
Biochemistry & Molecular Biology
Francesco Agostini, Anna Masato, Luigi Bubacco, Marco Bisaglia
Summary: This article reviews the potential mechanisms and clinical applications of metformin in the treatment of Parkinson's disease. Studies have shown that metformin may exert neuroprotective effects by regulating cellular pathways such as autophagy, degradation of pathological proteins, and mitochondrial function. Epidemiological studies on the correlation between long-term metformin use and the risk of developing Parkinson's disease are also discussed. However, there is controversy regarding the results obtained from experimental models and clinical studies, and further research is needed to clarify the mechanisms and efficacy of metformin in the treatment of Parkinson's disease.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Clinical Neurology
F. Stocchi, L. Vacca, P. Grassini, C. Tomino, G. Caminiti, M. Casali, V. D'Antoni, M. Volterrani, M. Torti
Summary: The study demonstrates that overnight switch from rasagiline to safinamide is safe and well tolerated by patients, without causing serotonin syndrome or hypertensive crisis. Short-term substitution of these two drugs did not result in adverse effects on blood pressure in most patients.
EUROPEAN JOURNAL OF NEUROLOGY
(2021)
Article
Neurosciences
Efthalia Angelopoulou, Yam Nath Paudel, Christina Piperi
Summary: Parkinson's disease, the most common neurodegenerative movement disorder, currently lacks disease-modifying treatment options and relies on symptomatic therapies. While neurotrophic factors have shown promise as a therapeutic approach, challenges remain in clinical trials with substances like glial-derived neurotrophic factor, prompting exploration of alternatives like liver growth factor (LGF). LGF has shown potential in promoting neural growth and survival through various mechanisms, offering new possibilities for PD treatment. Understanding the underlying molecular pathways could provide novel therapeutic opportunities for this debilitating disease.
MOLECULAR NEUROBIOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Magdalena Kondeva-Burdina, Emilio Mateev, Borislav Angelov, Virginia Tzankova, Maya Georgieva
Summary: Parkinson's disease is a significant burden in modern medicine. Current antiparkinsonian therapy has the limitation of only addressing the symptoms. This study aimed to find new derivatives that not only protect dopaminergic neurons but also reduce oxidative damage. The results identified ethyl 5-(4-bromophenyl)-1-(3-hydrazinyl-3-oxopropyl)-2-methyl-1H-pyrrole-3-carboxylate (12) as the most promising compound with low neurotoxicity and high neuroprotection, comparable to the reference drug Selegiline.
Article
Chemistry, Medicinal
Urte Sachleviciute, Gabriel Gonzalez, Marie Kvasnicova, Sarka Stepankova, Neringa Kleiziene, Aurimas Bieliauskas, Marek Zatloukal, Miroslav Strnad, Frank A. Slok, Miroslav Kvasnica, Algirdas Sackus, Asta Zukauskaite
Summary: A library of 3-aryl-3-azetidinyl acetic acid methyl ester derivatives was synthesized and evaluated for neuroprotective activity in salsolinol- and glutamate-induced neurodegeneration models. Compound 28 showed the highest neuroprotective effect, which may be driven by reductions in oxidative stress and caspase-3/7 activity.
ARCHIV DER PHARMAZIE
(2023)
Article
Engineering, Biomedical
Katherine E. Olson, Krista L. Namminga, Yaman Lu, Mackenzie J. Thurston, Aaron D. Schwab, Seymour de Picciotto, Sze-Wah Tse, William Walker, Jared Iacovelli, Clayton Small, Brian T. Wipke, R. Lee Mosley, Eric Huang, Howard E. Gendelman
Summary: Restoring the number and function of regulatory T cells through the use of lipid nanoparticles containing GM-CSF mRNA has shown promising results in preclinical Parkinson's disease models, with dose-dependent increases in Treg populations and neuroprotection seen after treatment. This approach represents a novel therapeutic strategy for neurodegenerative disorders by harnessing immune modulation to enhance adaptive immune function.
Review
Biochemistry & Molecular Biology
Sergio Davinelli, Sawan Ali, Vincenzo Solfrizzi, Giovanni Scapagnini, Graziamaria Corbi
Summary: Recent evidence suggests that diet can modify the risk of future cognitive impairment and dementia. Carotenoid interventions have shown significant effects on cognitive outcomes and may help reduce the risk of cognitive impairment and dementia.
Article
Biochemistry & Molecular Biology
Diego Sucunza, Alberto J. Rico, Elvira Roda, Maria Collantes, Gloria Gonzalez-Aseguinolaza, Ana I. Rodriguez-Perez, Ivan Penuelas, Alfonso Vazquez, Jose L. Labandeira-Garcia, Vania Broccoli, Jose L. Lanciego
Summary: Mutations in the GBA1 gene are the main genetic risk factor for Parkinson's disease, and enhancing GCase activity can reduce alpha-synuclein burden and prevent dopaminergic cell death. Gene therapy targeting GCase can improve survival of dopaminergic neurons and serve as a disease-modifying treatment for PD and related synucleinopathies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Medicine, General & Internal
Puyu Li, Ningdi Luo, Sainan Sun, Yuanyuan Li, Dingding Shen, Xue Zhu, Liche Zhou, Haiyan Zhou, Jun Liu
Summary: The NET-PD study is a clinical trial assessing the long-term neuroprotective effect of intermittent theta burst stimulation (iTBS) in Parkinson's disease (PD) patients. With a sample size of 60 PD patients, the study aims to clarify the clinical improvement and dynamic neuronal changes in PD patients using clinical assessment and multi-modal markers.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Chun-Yuan Cheng, Lassina Barro, Shang-Ting Tsai, Tai-Wei Feng, Xiao-Yu Wu, Che-Wei Chao, Ruei-Siang Yu, Ting-Yu Chin, Ming Fa Hsieh
Summary: The use of EGCG-loaded liposomes can effectively inhibit neuroinflammation induced by LPS, protect neurons, and improve motor impairment. This treatment approach has the potential to be a valuable candidate for disease-modifying therapy for Parkinson's disease.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Physiology
Francesco Fischetti, Luca Poli, Marina De Tommaso, Damiano Paolicelli, Gianpiero Greco, Stefania Cataldi
Summary: Physical activity has been shown to reduce the risk of developing non-communicable diseases, including neurodegenerative diseases, but the mechanisms involved are not fully understood. Recent research suggests that extracellular vesicles, which carry microRNAs, may play a role in mediating the beneficial effects of exercise on preventing and slowing neurodegenerative diseases. However, more studies are needed to understand how different exercise parameters may affect these vesicles and the microRNAs they carry.
FRONTIERS IN PHYSIOLOGY
(2023)